nodes	percent_of_prediction	percent_of_DWPC	metapath
Glyburide—CYP3A4—bone cancer	0.255	1	CbGaD
Glyburide—ABCC3—Cisplatin—bone cancer	0.0669	0.107	CbGbCtD
Glyburide—ABCC1—Epirubicin—bone cancer	0.0518	0.0831	CbGbCtD
Glyburide—ABCC3—Doxorubicin—bone cancer	0.0448	0.0719	CbGbCtD
Glyburide—ABCC3—Methotrexate—bone cancer	0.0434	0.0697	CbGbCtD
Glyburide—ABCB11—Doxorubicin—bone cancer	0.0387	0.0621	CbGbCtD
Glyburide—ABCC2—Carboplatin—bone cancer	0.0356	0.0571	CbGbCtD
Glyburide—SLC22A7—Methotrexate—bone cancer	0.034	0.0545	CbGbCtD
Glyburide—ABCG2—Carboplatin—bone cancer	0.0322	0.0516	CbGbCtD
Glyburide—ABCC2—Cisplatin—bone cancer	0.0304	0.0488	CbGbCtD
Glyburide—ABCC1—Doxorubicin—bone cancer	0.0275	0.0441	CbGbCtD
Glyburide—ABCG2—Cisplatin—bone cancer	0.0275	0.0441	CbGbCtD
Glyburide—ABCC1—Methotrexate—bone cancer	0.0267	0.0428	CbGbCtD
Glyburide—SLCO1A2—Methotrexate—bone cancer	0.0238	0.0382	CbGbCtD
Glyburide—ABCC2—Doxorubicin—bone cancer	0.0204	0.0327	CbGbCtD
Glyburide—ABCC2—Methotrexate—bone cancer	0.0197	0.0317	CbGbCtD
Glyburide—ABCG2—Doxorubicin—bone cancer	0.0184	0.0295	CbGbCtD
Glyburide—ABCG2—Methotrexate—bone cancer	0.0178	0.0286	CbGbCtD
Glyburide—SLC22A6—Methotrexate—bone cancer	0.0144	0.0232	CbGbCtD
Glyburide—ALB—Methotrexate—bone cancer	0.0123	0.0197	CbGbCtD
Glyburide—CYP2C9—Cisplatin—bone cancer	0.0102	0.0164	CbGbCtD
Glyburide—ABCB1—Cisplatin—bone cancer	0.00991	0.0159	CbGbCtD
Glyburide—ABCB1—Doxorubicin—bone cancer	0.00664	0.0107	CbGbCtD
Glyburide—ABCB1—Methotrexate—bone cancer	0.00643	0.0103	CbGbCtD
Glyburide—CYP3A4—Doxorubicin—bone cancer	0.00398	0.00638	CbGbCtD
Glyburide—CFTR—nose—bone cancer	0.00165	0.445	CbGeAlD
Glyburide—Myelosuppression—Cisplatin—bone cancer	0.00151	0.027	CcSEcCtD
Glyburide—Lactic acidosis—Epirubicin—bone cancer	0.00149	0.0266	CcSEcCtD
Glyburide—Lactic acidosis—Doxorubicin—bone cancer	0.00138	0.0247	CcSEcCtD
Glyburide—Blindness—Cisplatin—bone cancer	0.00128	0.0229	CcSEcCtD
Glyburide—Allergic cutaneous angiitis—Methotrexate—bone cancer	0.00122	0.0219	CcSEcCtD
Glyburide—Inappropriate antidiuretic hormone secretion—Cisplatin—bone cancer	0.00122	0.0218	CcSEcCtD
Glyburide—Reaction gastrointestinal—Methotrexate—bone cancer	0.00117	0.0208	CcSEcCtD
Glyburide—Nephropathy—Methotrexate—bone cancer	0.000817	0.0146	CcSEcCtD
Glyburide—Leukocytoclastic vasculitis—Methotrexate—bone cancer	0.000794	0.0142	CcSEcCtD
Glyburide—Myelosuppression—Epirubicin—bone cancer	0.000777	0.0139	CcSEcCtD
Glyburide—Kidney function abnormal—Epirubicin—bone cancer	0.000754	0.0135	CcSEcCtD
Glyburide—KCNJ1—appendage—bone cancer	0.000741	0.2	CbGeAlD
Glyburide—Myelosuppression—Doxorubicin—bone cancer	0.000719	0.0128	CcSEcCtD
Glyburide—Kidney function abnormal—Doxorubicin—bone cancer	0.000697	0.0125	CcSEcCtD
Glyburide—Blindness—Epirubicin—bone cancer	0.000658	0.0118	CcSEcCtD
Glyburide—Eruption—Methotrexate—bone cancer	0.000633	0.0113	CcSEcCtD
Glyburide—Zafirlukast—CYP3A4—bone cancer	0.00062	0.384	CrCbGaD
Glyburide—Blindness—Doxorubicin—bone cancer	0.000609	0.0109	CcSEcCtD
Glyburide—Encephalopathy—Methotrexate—bone cancer	0.000606	0.0108	CcSEcCtD
Glyburide—Eruption—Epirubicin—bone cancer	0.000592	0.0106	CcSEcCtD
Glyburide—Deafness—Cisplatin—bone cancer	0.000576	0.0103	CcSEcCtD
Glyburide—Glipizide—CYP3A4—bone cancer	0.000574	0.356	CrCbGaD
Glyburide—Haemolytic anaemia—Cisplatin—bone cancer	0.00057	0.0102	CcSEcCtD
Glyburide—Renal failure acute—Cisplatin—bone cancer	0.000558	0.00996	CcSEcCtD
Glyburide—Eruption—Doxorubicin—bone cancer	0.000548	0.00979	CcSEcCtD
Glyburide—Hyponatraemia—Cisplatin—bone cancer	0.000517	0.00923	CcSEcCtD
Glyburide—Pancreatitis—Cisplatin—bone cancer	0.000436	0.00779	CcSEcCtD
Glyburide—Sweating increased—Cisplatin—bone cancer	0.000433	0.00774	CcSEcCtD
Glyburide—Hyperbilirubinaemia—Methotrexate—bone cancer	0.000428	0.00764	CcSEcCtD
Glyburide—Pancytopenia—Cisplatin—bone cancer	0.000423	0.00755	CcSEcCtD
Glyburide—Bezafibrate—CYP3A4—bone cancer	0.000419	0.26	CrCbGaD
Glyburide—Jaundice cholestatic—Epirubicin—bone cancer	0.000415	0.0074	CcSEcCtD
Glyburide—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000401	0.00715	CcSEcCtD
Glyburide—Vasculitis—Methotrexate—bone cancer	0.000399	0.00712	CcSEcCtD
Glyburide—Jaundice cholestatic—Doxorubicin—bone cancer	0.000384	0.00685	CcSEcCtD
Glyburide—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000371	0.00662	CcSEcCtD
Glyburide—Aplastic anaemia—Methotrexate—bone cancer	0.000365	0.00653	CcSEcCtD
Glyburide—Visual impairment—Cisplatin—bone cancer	0.000343	0.00613	CcSEcCtD
Glyburide—Aplastic anaemia—Epirubicin—bone cancer	0.000342	0.00611	CcSEcCtD
Glyburide—Eye disorder—Cisplatin—bone cancer	0.000333	0.00595	CcSEcCtD
Glyburide—Aplastic anaemia—Doxorubicin—bone cancer	0.000316	0.00565	CcSEcCtD
Glyburide—Alopecia—Cisplatin—bone cancer	0.000315	0.00562	CcSEcCtD
Glyburide—Hepatic failure—Methotrexate—bone cancer	0.000314	0.00562	CcSEcCtD
Glyburide—Malnutrition—Cisplatin—bone cancer	0.00031	0.00554	CcSEcCtD
Glyburide—Erythema—Cisplatin—bone cancer	0.00031	0.00554	CcSEcCtD
Glyburide—Renal failure acute—Methotrexate—bone cancer	0.000306	0.00547	CcSEcCtD
Glyburide—Hepatic function abnormal—Epirubicin—bone cancer	0.000303	0.0054	CcSEcCtD
Glyburide—Visual disturbance—Methotrexate—bone cancer	0.000298	0.00533	CcSEcCtD
Glyburide—Vascular purpura—Epirubicin—bone cancer	0.000296	0.00528	CcSEcCtD
Glyburide—Hepatic failure—Epirubicin—bone cancer	0.000294	0.00525	CcSEcCtD
Glyburide—Vision blurred—Cisplatin—bone cancer	0.000292	0.00522	CcSEcCtD
Glyburide—Tremor—Cisplatin—bone cancer	0.00029	0.00519	CcSEcCtD
Glyburide—Anaemia—Cisplatin—bone cancer	0.000287	0.00512	CcSEcCtD
Glyburide—Renal failure acute—Epirubicin—bone cancer	0.000286	0.00512	CcSEcCtD
Glyburide—KCNJ5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000283	0.00472	CbGpPWpGaD
Glyburide—KCNJ11—Integration of energy metabolism—GNA11—bone cancer	0.000283	0.00472	CbGpPWpGaD
Glyburide—Hepatic function abnormal—Doxorubicin—bone cancer	0.00028	0.005	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—GNA11—bone cancer	0.000279	0.00465	CbGpPWpGaD
Glyburide—Renal impairment—Epirubicin—bone cancer	0.000278	0.00496	CcSEcCtD
Glyburide—Leukopenia—Cisplatin—bone cancer	0.000278	0.00496	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—EZH2—bone cancer	0.000277	0.00463	CbGpPWpGaD
Glyburide—Dermatitis bullous—Epirubicin—bone cancer	0.000277	0.00494	CcSEcCtD
Glyburide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000275	0.00459	CbGpPWpGaD
Glyburide—Purpura—Epirubicin—bone cancer	0.000274	0.0049	CcSEcCtD
Glyburide—Vascular purpura—Doxorubicin—bone cancer	0.000273	0.00488	CcSEcCtD
Glyburide—ABCC9—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000273	0.00456	CbGpPWpGaD
Glyburide—Hepatic failure—Doxorubicin—bone cancer	0.000272	0.00486	CcSEcCtD
Glyburide—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000271	0.00452	CbGpPWpGaD
Glyburide—Hypoglycaemia—Epirubicin—bone cancer	0.000271	0.00484	CcSEcCtD
Glyburide—Convulsion—Cisplatin—bone cancer	0.000269	0.0048	CcSEcCtD
Glyburide—Hyponatraemia—Epirubicin—bone cancer	0.000265	0.00474	CcSEcCtD
Glyburide—Renal failure acute—Doxorubicin—bone cancer	0.000265	0.00473	CcSEcCtD
Glyburide—Diplopia—Epirubicin—bone cancer	0.000264	0.00472	CcSEcCtD
Glyburide—Myalgia—Cisplatin—bone cancer	0.000264	0.00471	CcSEcCtD
Glyburide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000261	0.00435	CbGpPWpGaD
Glyburide—Renal impairment—Doxorubicin—bone cancer	0.000257	0.00459	CcSEcCtD
Glyburide—Dermatitis bullous—Doxorubicin—bone cancer	0.000256	0.00457	CcSEcCtD
Glyburide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000255	0.00426	CbGpPWpGaD
Glyburide—KCNJ5—Transmission across Chemical Synapses—BRAF—bone cancer	0.000254	0.00424	CbGpPWpGaD
Glyburide—Purpura—Doxorubicin—bone cancer	0.000254	0.00453	CcSEcCtD
Glyburide—Oedema—Cisplatin—bone cancer	0.000253	0.00452	CcSEcCtD
Glyburide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000251	0.00419	CbGpPWpGaD
Glyburide—Hypoglycaemia—Doxorubicin—bone cancer	0.000251	0.00448	CcSEcCtD
Glyburide—Nervous system disorder—Cisplatin—bone cancer	0.000248	0.00443	CcSEcCtD
Glyburide—Thrombocytopenia—Cisplatin—bone cancer	0.000248	0.00443	CcSEcCtD
Glyburide—Hyponatraemia—Doxorubicin—bone cancer	0.000246	0.00439	CcSEcCtD
Glyburide—Diplopia—Doxorubicin—bone cancer	0.000245	0.00437	CcSEcCtD
Glyburide—Hyperhidrosis—Cisplatin—bone cancer	0.000245	0.00437	CcSEcCtD
Glyburide—Eosinophilia—Methotrexate—bone cancer	0.000242	0.00432	CcSEcCtD
Glyburide—Anorexia—Cisplatin—bone cancer	0.000241	0.00431	CcSEcCtD
Glyburide—Pancreatitis—Methotrexate—bone cancer	0.000239	0.00428	CcSEcCtD
Glyburide—Hypotension—Cisplatin—bone cancer	0.000236	0.00422	CcSEcCtD
Glyburide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000233	0.00388	CbGpPWpGaD
Glyburide—Pancytopenia—Methotrexate—bone cancer	0.000232	0.00414	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000231	0.00412	CcSEcCtD
Glyburide—Abdominal distension—Epirubicin—bone cancer	0.00023	0.00411	CcSEcCtD
Glyburide—Paraesthesia—Cisplatin—bone cancer	0.000227	0.00406	CcSEcCtD
Glyburide—Eosinophilia—Epirubicin—bone cancer	0.000226	0.00404	CcSEcCtD
Glyburide—Dyspnoea—Cisplatin—bone cancer	0.000226	0.00403	CcSEcCtD
Glyburide—Pancreatitis—Epirubicin—bone cancer	0.000224	0.004	CcSEcCtD
Glyburide—Photosensitivity reaction—Methotrexate—bone cancer	0.000223	0.00398	CcSEcCtD
Glyburide—Decreased appetite—Cisplatin—bone cancer	0.00022	0.00393	CcSEcCtD
Glyburide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000218	0.0039	CcSEcCtD
Glyburide—Pancytopenia—Epirubicin—bone cancer	0.000217	0.00388	CcSEcCtD
Glyburide—ABCA1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000217	0.00362	CbGpPWpGaD
Glyburide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000216	0.00361	CbGpPWpGaD
Glyburide—CPT1A—connective tissue—bone cancer	0.000216	0.0584	CbGeAlD
Glyburide—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000214	0.00357	CbGpPWpGaD
Glyburide—Abdominal distension—Doxorubicin—bone cancer	0.000213	0.0038	CcSEcCtD
Glyburide—KCNJ5—Transmission across Chemical Synapses—MDM2—bone cancer	0.000213	0.00355	CbGpPWpGaD
Glyburide—Eosinophilia—Doxorubicin—bone cancer	0.000209	0.00374	CcSEcCtD
Glyburide—Photosensitivity reaction—Epirubicin—bone cancer	0.000209	0.00373	CcSEcCtD
Glyburide—Feeling abnormal—Cisplatin—bone cancer	0.000209	0.00372	CcSEcCtD
Glyburide—Pancreatitis—Doxorubicin—bone cancer	0.000207	0.0037	CcSEcCtD
Glyburide—Agranulocytosis—Methotrexate—bone cancer	0.000203	0.00363	CcSEcCtD
Glyburide—ABCA1—connective tissue—bone cancer	0.000201	0.0544	CbGeAlD
Glyburide—Pancytopenia—Doxorubicin—bone cancer	0.000201	0.00359	CcSEcCtD
Glyburide—Jaundice—Epirubicin—bone cancer	0.000199	0.00355	CcSEcCtD
Glyburide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000196	0.00328	CbGpPWpGaD
Glyburide—Hepatitis—Methotrexate—bone cancer	0.000195	0.00349	CcSEcCtD
Glyburide—KCNJ5—Neuronal System—BRAF—bone cancer	0.000195	0.00325	CbGpPWpGaD
Glyburide—Photosensitivity reaction—Doxorubicin—bone cancer	0.000193	0.00345	CcSEcCtD
Glyburide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000193	0.00322	CbGpPWpGaD
Glyburide—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000192	0.0032	CbGpPWpGaD
Glyburide—Agranulocytosis—Epirubicin—bone cancer	0.00019	0.0034	CcSEcCtD
Glyburide—Visual impairment—Methotrexate—bone cancer	0.000188	0.00336	CcSEcCtD
Glyburide—Hypersensitivity—Cisplatin—bone cancer	0.000186	0.00333	CcSEcCtD
Glyburide—Jaundice—Doxorubicin—bone cancer	0.000184	0.00328	CcSEcCtD
Glyburide—Hepatitis—Epirubicin—bone cancer	0.000183	0.00327	CcSEcCtD
Glyburide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000183	0.00305	CbGpPWpGaD
Glyburide—Eye disorder—Methotrexate—bone cancer	0.000183	0.00326	CcSEcCtD
Glyburide—Asthenia—Cisplatin—bone cancer	0.000182	0.00324	CcSEcCtD
Glyburide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000179	0.00299	CbGpPWpGaD
Glyburide—Visual impairment—Epirubicin—bone cancer	0.000176	0.00315	CcSEcCtD
Glyburide—Agranulocytosis—Doxorubicin—bone cancer	0.000176	0.00314	CcSEcCtD
Glyburide—Diarrhoea—Cisplatin—bone cancer	0.000173	0.00309	CcSEcCtD
Glyburide—Alopecia—Methotrexate—bone cancer	0.000173	0.00308	CcSEcCtD
Glyburide—ABCA1—Metabolism—NDUFA12—bone cancer	0.000172	0.00286	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—NDUFA12—bone cancer	0.000172	0.00286	CbGpPWpGaD
Glyburide—Eye disorder—Epirubicin—bone cancer	0.000171	0.00305	CcSEcCtD
Glyburide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000171	0.00285	CbGpPWpGaD
Glyburide—Malnutrition—Methotrexate—bone cancer	0.00017	0.00304	CcSEcCtD
Glyburide—Erythema—Methotrexate—bone cancer	0.00017	0.00304	CcSEcCtD
Glyburide—Hepatitis—Doxorubicin—bone cancer	0.000169	0.00302	CcSEcCtD
Glyburide—Visual impairment—Doxorubicin—bone cancer	0.000163	0.00291	CcSEcCtD
Glyburide—KCNJ5—Neuronal System—MDM2—bone cancer	0.000163	0.00272	CbGpPWpGaD
Glyburide—ABCA1—Folate Metabolism—TP53—bone cancer	0.000162	0.00271	CbGpPWpGaD
Glyburide—Alopecia—Epirubicin—bone cancer	0.000162	0.00289	CcSEcCtD
Glyburide—Vomiting—Cisplatin—bone cancer	0.000161	0.00287	CcSEcCtD
Glyburide—Vision blurred—Methotrexate—bone cancer	0.00016	0.00286	CcSEcCtD
Glyburide—Rash—Cisplatin—bone cancer	0.00016	0.00285	CcSEcCtD
Glyburide—Dermatitis—Cisplatin—bone cancer	0.000159	0.00285	CcSEcCtD
Glyburide—Malnutrition—Epirubicin—bone cancer	0.000159	0.00284	CcSEcCtD
Glyburide—Erythema—Epirubicin—bone cancer	0.000159	0.00284	CcSEcCtD
Glyburide—Eye disorder—Doxorubicin—bone cancer	0.000158	0.00282	CcSEcCtD
Glyburide—Anaemia—Methotrexate—bone cancer	0.000157	0.00281	CcSEcCtD
Glyburide—CPT1A—AMPK Signaling—TP53—bone cancer	0.000157	0.00261	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—CDK4—bone cancer	0.000157	0.00261	CbGpPWpGaD
Glyburide—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000154	0.00258	CbGpPWpGaD
Glyburide—ABCC9—Neuronal System—BRAF—bone cancer	0.000154	0.00257	CbGpPWpGaD
Glyburide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000153	0.00256	CbGpPWpGaD
Glyburide—Leukopenia—Methotrexate—bone cancer	0.000152	0.00272	CcSEcCtD
Glyburide—Nausea—Cisplatin—bone cancer	0.00015	0.00268	CcSEcCtD
Glyburide—Vision blurred—Epirubicin—bone cancer	0.00015	0.00268	CcSEcCtD
Glyburide—Alopecia—Doxorubicin—bone cancer	0.00015	0.00267	CcSEcCtD
Glyburide—CPT1A—tendon—bone cancer	0.000148	0.0401	CbGeAlD
Glyburide—Convulsion—Methotrexate—bone cancer	0.000147	0.00263	CcSEcCtD
Glyburide—Erythema—Doxorubicin—bone cancer	0.000147	0.00263	CcSEcCtD
Glyburide—Malnutrition—Doxorubicin—bone cancer	0.000147	0.00263	CcSEcCtD
Glyburide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000147	0.00246	CbGpPWpGaD
Glyburide—Anaemia—Epirubicin—bone cancer	0.000147	0.00263	CcSEcCtD
Glyburide—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000146	0.00243	CbGpPWpGaD
Glyburide—Myalgia—Methotrexate—bone cancer	0.000145	0.00259	CcSEcCtD
Glyburide—Arthralgia—Methotrexate—bone cancer	0.000145	0.00259	CcSEcCtD
Glyburide—ALB—Folate Metabolism—DHFR—bone cancer	0.000145	0.00242	CbGpPWpGaD
Glyburide—Leukopenia—Epirubicin—bone cancer	0.000143	0.00255	CcSEcCtD
Glyburide—ABCA1—Metabolism—NT5C3A—bone cancer	0.000142	0.00237	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—NT5C3A—bone cancer	0.000142	0.00237	CbGpPWpGaD
Glyburide—Confusional state—Methotrexate—bone cancer	0.00014	0.0025	CcSEcCtD
Glyburide—Vision blurred—Doxorubicin—bone cancer	0.000139	0.00248	CcSEcCtD
Glyburide—Convulsion—Epirubicin—bone cancer	0.000138	0.00246	CcSEcCtD
Glyburide—Nervous system disorder—Methotrexate—bone cancer	0.000136	0.00243	CcSEcCtD
Glyburide—Anaemia—Doxorubicin—bone cancer	0.000136	0.00243	CcSEcCtD
Glyburide—Thrombocytopenia—Methotrexate—bone cancer	0.000136	0.00243	CcSEcCtD
Glyburide—Myalgia—Epirubicin—bone cancer	0.000136	0.00242	CcSEcCtD
Glyburide—Arthralgia—Epirubicin—bone cancer	0.000136	0.00242	CcSEcCtD
Glyburide—ABCC8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000136	0.00226	CbGpPWpGaD
Glyburide—Hyperhidrosis—Methotrexate—bone cancer	0.000134	0.0024	CcSEcCtD
Glyburide—ABCA1—spinal cord—bone cancer	0.000133	0.0361	CbGeAlD
Glyburide—Anorexia—Methotrexate—bone cancer	0.000132	0.00236	CcSEcCtD
Glyburide—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	0.000132	0.00221	CbGpPWpGaD
Glyburide—Leukopenia—Doxorubicin—bone cancer	0.000132	0.00236	CcSEcCtD
Glyburide—Confusional state—Epirubicin—bone cancer	0.000131	0.00234	CcSEcCtD
Glyburide—ABCC3—NRF2 pathway—TGFBR2—bone cancer	0.000131	0.00218	CbGpPWpGaD
Glyburide—ABCC3—NRF2 pathway—GSTP1—bone cancer	0.000131	0.00218	CbGpPWpGaD
Glyburide—Oedema—Epirubicin—bone cancer	0.00013	0.00232	CcSEcCtD
Glyburide—Hypotension—Methotrexate—bone cancer	0.00013	0.00232	CcSEcCtD
Glyburide—KCNJ1—Neuronal System—BRAF—bone cancer	0.000129	0.00215	CbGpPWpGaD
Glyburide—ABCC9—Neuronal System—MDM2—bone cancer	0.000129	0.00215	CbGpPWpGaD
Glyburide—Shock—Epirubicin—bone cancer	0.000128	0.00228	CcSEcCtD
Glyburide—Convulsion—Doxorubicin—bone cancer	0.000128	0.00228	CcSEcCtD
Glyburide—Nervous system disorder—Epirubicin—bone cancer	0.000127	0.00228	CcSEcCtD
Glyburide—Thrombocytopenia—Epirubicin—bone cancer	0.000127	0.00227	CcSEcCtD
Glyburide—ALB—Platelet degranulation—SPARC—bone cancer	0.000127	0.00212	CbGpPWpGaD
Glyburide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000127	0.00226	CcSEcCtD
Glyburide—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000126	0.0021	CbGpPWpGaD
Glyburide—Hyperhidrosis—Epirubicin—bone cancer	0.000126	0.00224	CcSEcCtD
Glyburide—Arthralgia—Doxorubicin—bone cancer	0.000125	0.00224	CcSEcCtD
Glyburide—Myalgia—Doxorubicin—bone cancer	0.000125	0.00224	CcSEcCtD
Glyburide—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000125	0.00209	CbGpPWpGaD
Glyburide—Paraesthesia—Methotrexate—bone cancer	0.000125	0.00223	CcSEcCtD
Glyburide—Anorexia—Epirubicin—bone cancer	0.000124	0.00221	CcSEcCtD
Glyburide—Dyspnoea—Methotrexate—bone cancer	0.000124	0.00221	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000124	0.00206	CbGpPWpGaD
Glyburide—Dyspepsia—Methotrexate—bone cancer	0.000122	0.00218	CcSEcCtD
Glyburide—SLC15A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000122	0.00204	CbGpPWpGaD
Glyburide—Hypotension—Epirubicin—bone cancer	0.000121	0.00217	CcSEcCtD
Glyburide—Confusional state—Doxorubicin—bone cancer	0.000121	0.00217	CcSEcCtD
Glyburide—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000121	0.00202	CbGpPWpGaD
Glyburide—Decreased appetite—Methotrexate—bone cancer	0.000121	0.00216	CcSEcCtD
Glyburide—Oedema—Doxorubicin—bone cancer	0.00012	0.00215	CcSEcCtD
Glyburide—Gastrointestinal disorder—Methotrexate—bone cancer	0.00012	0.00214	CcSEcCtD
Glyburide—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00012	0.002	CbGpPWpGaD
Glyburide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000119	0.00198	CbGpPWpGaD
Glyburide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000118	0.00211	CcSEcCtD
Glyburide—Shock—Doxorubicin—bone cancer	0.000118	0.00211	CcSEcCtD
Glyburide—Nervous system disorder—Doxorubicin—bone cancer	0.000118	0.00211	CcSEcCtD
Glyburide—Thrombocytopenia—Doxorubicin—bone cancer	0.000118	0.0021	CcSEcCtD
Glyburide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000117	0.00196	CbGpPWpGaD
Glyburide—ABCC8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000117	0.00195	CbGpPWpGaD
Glyburide—Paraesthesia—Epirubicin—bone cancer	0.000117	0.00208	CcSEcCtD
Glyburide—Hyperhidrosis—Doxorubicin—bone cancer	0.000116	0.00208	CcSEcCtD
Glyburide—Dyspnoea—Epirubicin—bone cancer	0.000116	0.00207	CcSEcCtD
Glyburide—Anorexia—Doxorubicin—bone cancer	0.000115	0.00205	CcSEcCtD
Glyburide—Feeling abnormal—Methotrexate—bone cancer	0.000114	0.00204	CcSEcCtD
Glyburide—Dyspepsia—Epirubicin—bone cancer	0.000114	0.00204	CcSEcCtD
Glyburide—Gastrointestinal pain—Methotrexate—bone cancer	0.000114	0.00203	CcSEcCtD
Glyburide—SLC15A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000113	0.00189	CbGpPWpGaD
Glyburide—Decreased appetite—Epirubicin—bone cancer	0.000113	0.00202	CcSEcCtD
Glyburide—Hypotension—Doxorubicin—bone cancer	0.000112	0.00201	CcSEcCtD
Glyburide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000112	0.002	CcSEcCtD
Glyburide—Urticaria—Methotrexate—bone cancer	0.00011	0.00197	CcSEcCtD
Glyburide—Abdominal pain—Methotrexate—bone cancer	0.00011	0.00196	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00011	0.00196	CcSEcCtD
Glyburide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000108	0.00181	CbGpPWpGaD
Glyburide—KCNJ1—Neuronal System—MDM2—bone cancer	0.000108	0.0018	CbGpPWpGaD
Glyburide—Paraesthesia—Doxorubicin—bone cancer	0.000108	0.00193	CcSEcCtD
Glyburide—Dyspnoea—Doxorubicin—bone cancer	0.000107	0.00191	CcSEcCtD
Glyburide—Feeling abnormal—Epirubicin—bone cancer	0.000107	0.00191	CcSEcCtD
Glyburide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000107	0.00178	CbGpPWpGaD
Glyburide—Gastrointestinal pain—Epirubicin—bone cancer	0.000106	0.0019	CcSEcCtD
Glyburide—ABCC8—Metabolism—NDUFA12—bone cancer	0.000106	0.00177	CbGpPWpGaD
Glyburide—Dyspepsia—Doxorubicin—bone cancer	0.000106	0.00189	CcSEcCtD
Glyburide—SLC15A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000105	0.00176	CbGpPWpGaD
Glyburide—Decreased appetite—Doxorubicin—bone cancer	0.000105	0.00187	CcSEcCtD
Glyburide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000104	0.00185	CcSEcCtD
Glyburide—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000104	0.00173	CbGpPWpGaD
Glyburide—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000104	0.00173	CbGpPWpGaD
Glyburide—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000103	0.00173	CbGpPWpGaD
Glyburide—Urticaria—Epirubicin—bone cancer	0.000103	0.00184	CcSEcCtD
Glyburide—KCNJ11—Metabolism—NDUFA12—bone cancer	0.000103	0.00171	CbGpPWpGaD
Glyburide—Abdominal pain—Epirubicin—bone cancer	0.000103	0.00183	CcSEcCtD
Glyburide—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000103	0.00171	CbGpPWpGaD
Glyburide—Hypersensitivity—Methotrexate—bone cancer	0.000102	0.00183	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—JUN—bone cancer	0.000101	0.00168	CbGpPWpGaD
Glyburide—Asthenia—Methotrexate—bone cancer	9.96e-05	0.00178	CcSEcCtD
Glyburide—Feeling abnormal—Doxorubicin—bone cancer	9.91e-05	0.00177	CcSEcCtD
Glyburide—Gastrointestinal pain—Doxorubicin—bone cancer	9.83e-05	0.00176	CcSEcCtD
Glyburide—Pruritus—Methotrexate—bone cancer	9.82e-05	0.00175	CcSEcCtD
Glyburide—SLC15A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.78e-05	0.00163	CbGpPWpGaD
Glyburide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.63e-05	0.00161	CbGpPWpGaD
Glyburide—Hypersensitivity—Epirubicin—bone cancer	9.57e-05	0.00171	CcSEcCtD
Glyburide—Urticaria—Doxorubicin—bone cancer	9.55e-05	0.00171	CcSEcCtD
Glyburide—Abdominal pain—Doxorubicin—bone cancer	9.51e-05	0.0017	CcSEcCtD
Glyburide—Diarrhoea—Methotrexate—bone cancer	9.5e-05	0.0017	CcSEcCtD
Glyburide—Asthenia—Epirubicin—bone cancer	9.32e-05	0.00167	CcSEcCtD
Glyburide—Pruritus—Epirubicin—bone cancer	9.19e-05	0.00164	CcSEcCtD
Glyburide—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	9.13e-05	0.00152	CbGpPWpGaD
Glyburide—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.94e-05	0.00149	CbGpPWpGaD
Glyburide—Diarrhoea—Epirubicin—bone cancer	8.89e-05	0.00159	CcSEcCtD
Glyburide—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.87e-05	0.00148	CbGpPWpGaD
Glyburide—Hypersensitivity—Doxorubicin—bone cancer	8.86e-05	0.00158	CcSEcCtD
Glyburide—Vomiting—Methotrexate—bone cancer	8.83e-05	0.00158	CcSEcCtD
Glyburide—KCNJ11—tendon—bone cancer	8.81e-05	0.0238	CbGeAlD
Glyburide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.78e-05	0.00147	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—NT5C3A—bone cancer	8.78e-05	0.00147	CbGpPWpGaD
Glyburide—Rash—Methotrexate—bone cancer	8.76e-05	0.00156	CcSEcCtD
Glyburide—Dermatitis—Methotrexate—bone cancer	8.75e-05	0.00156	CcSEcCtD
Glyburide—Headache—Methotrexate—bone cancer	8.7e-05	0.00155	CcSEcCtD
Glyburide—Asthenia—Doxorubicin—bone cancer	8.63e-05	0.00154	CcSEcCtD
Glyburide—KCNJ11—Metabolism—NT5C3A—bone cancer	8.51e-05	0.00142	CbGpPWpGaD
Glyburide—Pruritus—Doxorubicin—bone cancer	8.51e-05	0.00152	CcSEcCtD
Glyburide—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.41e-05	0.0014	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—NDUFA12—bone cancer	8.38e-05	0.0014	CbGpPWpGaD
Glyburide—Vomiting—Epirubicin—bone cancer	8.26e-05	0.00148	CcSEcCtD
Glyburide—Nausea—Methotrexate—bone cancer	8.25e-05	0.00147	CcSEcCtD
Glyburide—Diarrhoea—Doxorubicin—bone cancer	8.23e-05	0.00147	CcSEcCtD
Glyburide—Rash—Epirubicin—bone cancer	8.19e-05	0.00146	CcSEcCtD
Glyburide—Dermatitis—Epirubicin—bone cancer	8.19e-05	0.00146	CcSEcCtD
Glyburide—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.14e-05	0.00136	CbGpPWpGaD
Glyburide—Headache—Epirubicin—bone cancer	8.14e-05	0.00145	CcSEcCtD
Glyburide—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.05e-05	0.00134	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—NDUFA12—bone cancer	8.03e-05	0.00134	CbGpPWpGaD
Glyburide—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	8.02e-05	0.00134	CbGpPWpGaD
Glyburide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	7.96e-05	0.00133	CbGpPWpGaD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	7.94e-05	0.00133	CbGpPWpGaD
Glyburide—ABCC8—spinal cord—bone cancer	7.83e-05	0.0212	CbGeAlD
Glyburide—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.72e-05	0.00129	CbGpPWpGaD
Glyburide—Nausea—Epirubicin—bone cancer	7.72e-05	0.00138	CcSEcCtD
Glyburide—Vomiting—Doxorubicin—bone cancer	7.64e-05	0.00137	CcSEcCtD
Glyburide—Rash—Doxorubicin—bone cancer	7.58e-05	0.00135	CcSEcCtD
Glyburide—Dermatitis—Doxorubicin—bone cancer	7.57e-05	0.00135	CcSEcCtD
Glyburide—Headache—Doxorubicin—bone cancer	7.53e-05	0.00135	CcSEcCtD
Glyburide—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.26e-05	0.00121	CbGpPWpGaD
Glyburide—Nausea—Doxorubicin—bone cancer	7.14e-05	0.00128	CcSEcCtD
Glyburide—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.08e-05	0.00118	CbGpPWpGaD
Glyburide—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.03e-05	0.00117	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—NDUFA12—bone cancer	6.99e-05	0.00117	CbGpPWpGaD
Glyburide—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.95e-05	0.00116	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—NT5C3A—bone cancer	6.94e-05	0.00116	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—TP53—bone cancer	6.66e-05	0.00111	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—NT5C3A—bone cancer	6.65e-05	0.00111	CbGpPWpGaD
Glyburide—ABCC8—Neuronal System—BRAF—bone cancer	6.59e-05	0.0011	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.51e-05	0.00109	CbGpPWpGaD
Glyburide—KCNJ11—Neuronal System—BRAF—bone cancer	6.39e-05	0.00107	CbGpPWpGaD
Glyburide—SLCO2B1—tendon—bone cancer	6.35e-05	0.0172	CbGeAlD
Glyburide—ABCC1—Metabolism—NDUFA12—bone cancer	6.29e-05	0.00105	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—ENO2—bone cancer	6.23e-05	0.00104	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—ENO2—bone cancer	6.23e-05	0.00104	CbGpPWpGaD
Glyburide—SLCO2B1—spinal cord—bone cancer	6.13e-05	0.0166	CbGeAlD
Glyburide—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.11e-05	0.00102	CbGpPWpGaD
Glyburide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	6.09e-05	0.00102	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—NT5C3A—bone cancer	5.79e-05	0.000967	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—DHFR—bone cancer	5.78e-05	0.000964	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—DHFR—bone cancer	5.78e-05	0.000964	CbGpPWpGaD
Glyburide—SLCO1A2—spinal cord—bone cancer	5.64e-05	0.0153	CbGeAlD
Glyburide—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	5.62e-05	0.000939	CbGpPWpGaD
Glyburide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.55e-05	0.000927	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.54e-05	0.000924	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—NDUFA12—bone cancer	5.54e-05	0.000924	CbGpPWpGaD
Glyburide—ABCC8—Neuronal System—MDM2—bone cancer	5.52e-05	0.000921	CbGpPWpGaD
Glyburide—ABCC2—tendon—bone cancer	5.45e-05	0.0147	CbGeAlD
Glyburide—ABCA1—Metabolism—GNA11—bone cancer	5.4e-05	0.000901	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—GNA11—bone cancer	5.4e-05	0.000901	CbGpPWpGaD
Glyburide—KCNJ11—Neuronal System—MDM2—bone cancer	5.35e-05	0.000893	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—NT5C3A—bone cancer	5.21e-05	0.00087	CbGpPWpGaD
Glyburide—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.14e-05	0.000859	CbGpPWpGaD
Glyburide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.12e-05	0.000854	CbGpPWpGaD
Glyburide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.05e-05	0.000842	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.04e-05	0.000842	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—CYP3A4—bone cancer	4.89e-05	0.000817	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—CYP3A4—bone cancer	4.89e-05	0.000817	CbGpPWpGaD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.87e-05	0.000812	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.87e-05	0.000812	CbGpPWpGaD
Glyburide—ABCC1—tendon—bone cancer	4.8e-05	0.013	CbGeAlD
Glyburide—SLC15A2—spinal cord—bone cancer	4.68e-05	0.0127	CbGeAlD
Glyburide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.67e-05	0.000779	CbGpPWpGaD
Glyburide—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	4.66e-05	0.000778	CbGpPWpGaD
Glyburide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.6e-05	0.000768	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.59e-05	0.000766	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—NT5C3A—bone cancer	4.59e-05	0.000766	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.53e-05	0.000756	CbGpPWpGaD
Glyburide—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.38e-05	0.00073	CbGpPWpGaD
Glyburide—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.37e-05	0.000729	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	4.32e-05	0.00072	CbGpPWpGaD
Glyburide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.32e-05	0.00072	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.29e-05	0.000716	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—GSTP1—bone cancer	4.19e-05	0.000698	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—GSTP1—bone cancer	4.19e-05	0.000698	CbGpPWpGaD
Glyburide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.06e-05	0.000678	CbGpPWpGaD
Glyburide—CYP2C9—Biological oxidations—GSTP1—bone cancer	3.99e-05	0.000666	CbGpPWpGaD
Glyburide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.94e-05	0.000657	CbGpPWpGaD
Glyburide—ABCG2—bone marrow—bone cancer	3.85e-05	0.0104	CbGeAlD
Glyburide—ABCC8—Metabolism—ENO2—bone cancer	3.85e-05	0.000642	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.84e-05	0.000641	CbGpPWpGaD
Glyburide—ABCG2—spinal cord—bone cancer	3.83e-05	0.0104	CbGeAlD
Glyburide—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.83e-05	0.000639	CbGpPWpGaD
Glyburide—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.77e-05	0.00063	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—ENO2—bone cancer	3.73e-05	0.000622	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—DHFR—bone cancer	3.57e-05	0.000595	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—DHFR—bone cancer	3.46e-05	0.000577	CbGpPWpGaD
Glyburide—ALB—Metabolism—NDUFA12—bone cancer	3.42e-05	0.00057	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—GNA11—bone cancer	3.33e-05	0.000556	CbGpPWpGaD
Glyburide—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.31e-05	0.000552	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—TP53—bone cancer	3.23e-05	0.00054	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—GNA11—bone cancer	3.23e-05	0.00054	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—NDUFA12—bone cancer	3.07e-05	0.000512	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—ENO2—bone cancer	3.04e-05	0.000507	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—CYP3A4—bone cancer	3.02e-05	0.000505	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—NDUFA12—bone cancer	2.99e-05	0.0005	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—CYP3A4—bone cancer	2.93e-05	0.000489	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—ENO2—bone cancer	2.91e-05	0.000486	CbGpPWpGaD
Glyburide—ALB—Hemostasis—SPARC—bone cancer	2.9e-05	0.000484	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.85e-05	0.000475	CbGpPWpGaD
Glyburide—ALB—Metabolism—NT5C3A—bone cancer	2.83e-05	0.000472	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—DHFR—bone cancer	2.82e-05	0.000471	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—NDUFA12—bone cancer	2.8e-05	0.000467	CbGpPWpGaD
Glyburide—ABCC1—Disease—ENO2—bone cancer	2.73e-05	0.000455	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—DHFR—bone cancer	2.7e-05	0.000451	CbGpPWpGaD
Glyburide—ALB—Hemostasis—GNA11—bone cancer	2.65e-05	0.000443	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—GNA11—bone cancer	2.64e-05	0.00044	CbGpPWpGaD
Glyburide—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.63e-05	0.000439	CbGpPWpGaD
Glyburide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.6e-05	0.000433	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—GSTP1—bone cancer	2.59e-05	0.000431	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—NT5C3A—bone cancer	2.54e-05	0.000424	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—ENO2—bone cancer	2.54e-05	0.000424	CbGpPWpGaD
Glyburide—ABCC1—Disease—DHFR—bone cancer	2.53e-05	0.000422	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—GNA11—bone cancer	2.53e-05	0.000422	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—GSTP1—bone cancer	2.51e-05	0.000418	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—NT5C3A—bone cancer	2.48e-05	0.000414	CbGpPWpGaD
Glyburide—ALB—Hemostasis—IL3—bone cancer	2.4e-05	0.000401	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—CYP3A4—bone cancer	2.39e-05	0.000399	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.38e-05	0.000397	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—DHFR—bone cancer	2.35e-05	0.000393	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—NT5C3A—bone cancer	2.32e-05	0.000387	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—CYP3A4—bone cancer	2.29e-05	0.000382	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—ENO2—bone cancer	2.28e-05	0.000381	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.28e-05	0.00038	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—GNA11—bone cancer	2.2e-05	0.000367	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—PTGS2—bone cancer	2.17e-05	0.000362	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—PTGS2—bone cancer	2.17e-05	0.000362	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—DHFR—bone cancer	2.12e-05	0.000354	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.11e-05	0.000352	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—GSTP1—bone cancer	2.04e-05	0.000341	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.03e-05	0.00034	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—ENO2—bone cancer	2.01e-05	0.000335	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—CYP3A4—bone cancer	2e-05	0.000333	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.98e-05	0.000331	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—GNA11—bone cancer	1.98e-05	0.00033	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—GSTP1—bone cancer	1.96e-05	0.000327	CbGpPWpGaD
Glyburide—ABCB1—bone marrow—bone cancer	1.9e-05	0.00513	CbGeAlD
Glyburide—ABCB1—spinal cord—bone cancer	1.89e-05	0.00511	CbGeAlD
Glyburide—ABCG2—Metabolism—DHFR—bone cancer	1.86e-05	0.000311	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—NDUFA12—bone cancer	1.84e-05	0.000308	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.83e-05	0.000306	CbGpPWpGaD
Glyburide—ABCC1—Disease—TGFBR2—bone cancer	1.83e-05	0.000306	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—CYP3A4—bone cancer	1.8e-05	0.0003	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.79e-05	0.000298	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—GNA11—bone cancer	1.74e-05	0.000291	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—GSTP1—bone cancer	1.71e-05	0.000285	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—CYP3A4—bone cancer	1.58e-05	0.000264	CbGpPWpGaD
Glyburide—ALB—Hemostasis—PLAU—bone cancer	1.58e-05	0.000263	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—GSTP1—bone cancer	1.54e-05	0.000256	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—NT5C3A—bone cancer	1.53e-05	0.000255	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.44e-05	0.000241	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—GSTP1—bone cancer	1.35e-05	0.000225	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—PTGS2—bone cancer	1.34e-05	0.000224	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—PTGS2—bone cancer	1.3e-05	0.000217	CbGpPWpGaD
Glyburide—ABCC1—Disease—KIT—bone cancer	1.25e-05	0.000209	CbGpPWpGaD
Glyburide—ALB—Metabolism—ENO2—bone cancer	1.24e-05	0.000207	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.21e-05	0.000202	CbGpPWpGaD
Glyburide—ABCC1—Disease—BRAF—bone cancer	1.18e-05	0.000196	CbGpPWpGaD
Glyburide—ALB—Metabolism—DHFR—bone cancer	1.15e-05	0.000192	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—ENO2—bone cancer	1.11e-05	0.000186	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—ENO2—bone cancer	1.09e-05	0.000181	CbGpPWpGaD
Glyburide—ALB—Metabolism—GNA11—bone cancer	1.08e-05	0.000179	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—PTGS2—bone cancer	1.06e-05	0.000177	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—DHFR—bone cancer	1.03e-05	0.000172	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—PTGS2—bone cancer	1.02e-05	0.000169	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—ENO2—bone cancer	1.01e-05	0.000169	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—DHFR—bone cancer	1.01e-05	0.000168	CbGpPWpGaD
Glyburide—ABCC1—Disease—MDM2—bone cancer	9.85e-06	0.000164	CbGpPWpGaD
Glyburide—ALB—Metabolism—CYP3A4—bone cancer	9.75e-06	0.000163	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.7e-06	0.000162	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—GNA11—bone cancer	9.65e-06	0.000161	CbGpPWpGaD
Glyburide—ABCC1—Disease—PTGS2—bone cancer	9.5e-06	0.000159	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—GNA11—bone cancer	9.42e-06	0.000157	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—DHFR—bone cancer	9.42e-06	0.000157	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—PTGS2—bone cancer	8.84e-06	0.000148	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—GNA11—bone cancer	8.8e-06	0.000147	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—CYP3A4—bone cancer	8.75e-06	0.000146	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.71e-06	0.000145	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—CYP3A4—bone cancer	8.54e-06	0.000143	CbGpPWpGaD
Glyburide—ALB—Metabolism—GSTP1—bone cancer	8.34e-06	0.000139	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—CYP3A4—bone cancer	7.98e-06	0.000133	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—PTGS2—bone cancer	7.95e-06	0.000133	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.94e-06	0.000132	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—GSTP1—bone cancer	7.48e-06	0.000125	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—GSTP1—bone cancer	7.3e-06	0.000122	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—PTGS2—bone cancer	7e-06	0.000117	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—GSTP1—bone cancer	6.82e-06	0.000114	CbGpPWpGaD
Glyburide—ABCC1—Disease—EGFR—bone cancer	6.73e-06	0.000112	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—ENO2—bone cancer	6.69e-06	0.000112	CbGpPWpGaD
Glyburide—ALB—Hemostasis—TP53—bone cancer	6.34e-06	0.000106	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—DHFR—bone cancer	6.21e-06	0.000104	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—GNA11—bone cancer	5.8e-06	9.69e-05	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—GSTP1—bone cancer	4.5e-06	7.51e-05	CbGpPWpGaD
Glyburide—ALB—Metabolism—PTGS2—bone cancer	4.32e-06	7.21e-05	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—PTGS2—bone cancer	3.88e-06	6.47e-05	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—PTGS2—bone cancer	3.78e-06	6.32e-05	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—PTGS2—bone cancer	3.54e-06	5.9e-05	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—PTGS2—bone cancer	2.33e-06	3.89e-05	CbGpPWpGaD
